Your session is about to expire
← Back to Search
Single-Incision vs Retropubic Sling for Stress Urinary Incontinence (SASS Trial)
N/A
Recruiting
Led By Catherine A Matthews, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
At least 21 years of age
Vaginal bulge symptoms as indicated by an affirmative response of >1 to question 3 of the PFDI-SF20
Must not have
Poorly-controlled diabetes mellitus (HgbA1c > 9 within 3 months of surgery date)
Current genitourinary fistula or urethral diverticulum
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, surgery, post op: week 2, week 6, year 1, year 2, year 3, and year 5
Awards & highlights
No Placebo-Only Group
Summary
This trial will compare the effectiveness of a single-incision sling versus a retropubic sling for treating stress urinary incontinence during minimally invasive sacrocolpopexy.
Who is the study for?
Women over 21 with vaginal bulge symptoms, pelvic organ prolapse stage II or higher, and stress urinary incontinence are eligible. They must be able to consent, complete questionnaires, and return for follow-ups. Exclusions include neurogenic bladder issues, high post-void residuals, pregnancy plans, serious interfering conditions, unwillingness to have a synthetic sling, unresolved UTI's or poorly-controlled diabetes.
What is being tested?
The SASS trial is testing two surgical methods for treating stress urinary incontinence during minimally invasive sacrocolpopexy: the Single-incision Sling (SIS) versus the Retropubic Mid-Urethral Sling (RP Sling). It's a multicenter study where participants are randomly assigned to one of these treatments without knowing which one they receive.
What are the potential side effects?
Potential side effects may include discomfort at the incision site, bleeding or bruising around the area of surgery; there could also be risks related to anesthesia. Specific side effects related to each procedure will vary and can be discussed with healthcare providers.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am at least 21 years old.
Select...
I feel a bulge in my vagina, as per the PFDI-SF20 survey.
Select...
My pelvic organ prolapse is at least stage II with apical descent.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My diabetes is not well-managed with an HgbA1c over 9.
Select...
I have a current issue with abnormal connections in my urinary tract.
Select...
I have had radiation therapy to my pelvic area before.
Select...
I have had surgery for urinary leakage.
Select...
I have inflammatory bowel disease.
Select...
I use self-catheterization due to bladder issues.
Select...
I do not want a synthetic sling.
Select...
I have a current urinary tract infection that hasn't been treated.
Select...
I am scheduled for surgery related to bowel issues.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, surgery, post op: week 2, week 6, year 1, year 2, year 3, and year 5
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, surgery, post op: week 2, week 6, year 1, year 2, year 3, and year 5
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with subjectively bothersome stress incontinence
Secondary study objectives
Assessment of post-void residual (PVR) volume
Number of Participants needing Retreatment
Number of Participants needing bladder drainage
+5 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: SIS GroupExperimental Treatment1 Intervention
Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure
Group II: RP Sling GroupExperimental Treatment1 Intervention
Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure
Find a Location
Who is running the clinical trial?
Wake Forest University Health SciencesLead Sponsor
1,392 Previous Clinical Trials
2,452,682 Total Patients Enrolled
Boston Scientific CorporationIndustry Sponsor
743 Previous Clinical Trials
857,262 Total Patients Enrolled
Catherine A Matthews, MDPrincipal InvestigatorWake Forest University Health Sciences
3 Previous Clinical Trials
355 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have bladder issues not fixed by certain tests or devices.My diabetes is not well-managed with an HgbA1c over 9.You have been diagnosed with stress urinary incontinence based on a positive cough stress test or urodynamic study showing reduced prolapse.I have a current issue with abnormal connections in my urinary tract.I have had radiation therapy to my pelvic area before.I have had surgery for urinary leakage.I have inflammatory bowel disease.I am a woman being considered for a specific pelvic surgery.I am at least 21 years old.Currently in prison.I use self-catheterization due to bladder issues.I do not want a synthetic sling.I do not have any serious illness that could affect my participation in the study.I have a current urinary tract infection that hasn't been treated.I feel a bulge in my vagina, as per the PFDI-SF20 survey.I am scheduled for surgery related to bowel issues.My pelvic organ prolapse is at least stage II with apical descent.
Research Study Groups:
This trial has the following groups:- Group 1: SIS Group
- Group 2: RP Sling Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger